Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Vaccine Technology 2009 Conference

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment

Bioinformatics Market Potential

Biotechnology in the European Union; Trends, Investing & Country Profiles

China Pharmaceutical Industry: Analysis and Market Trends

European Generic Drug Market Potential

Global Biotechnology Markets Trends

Strategic Alliances in World Pharma and Biotech Markets

Understanding China's Chemical Industry

Understanding Genomics and Global Health Impacts

Understanding Pharmacogenomics

BioPortfolio | La Merie | Competitor Analysis: Human Growth Hormone (hGH)

Competitor Analysis: Human Growth Hormone (hGH)

The Competitive Intelligence Report Human Growth Hormone (hGH) as of October 2008 provides a competitor analysis in the development pipeline of biosimilar (biogeneric) versions of somatropin and next generation hGH products for treatment of growth hormone deficiency )GHD) in childrens and adults and related diseases. The report includes an evaluation of the hGH market size in 2007 based on published data and provides company pipelines in the field of hGH.

Human growth hormone (hGH; somatropin) was the first therapeutic protein for which a biosimilar version was approved in the US and in Europe in 2006. Novartis’ generic division Sandoz sells the generic somatropin as Omnitrope at a 25 % discount but only achieved 2007 sales of about US$ 8 mln representing a 0.3 % share of the worldwide hGH market in 2007 of US$ 2.7 bln (published data only). Although 2008 sales of Omnitrope are growing steadily, they can be expected to achieve only about US$ 30 mln (about 1 % of the ww market).

The number of mere copycat hGH biosimilars in regulated markets is rather limited to a total of three approved biosimilar versions in the EU and/or US and two other versions in the pipeline of 1st generation somatropin biogenerics. The majority of next generation products attempts to improve frequency of administration or delivery. To reduce frequency of SC injections, slow-release formulations are the clinically most advanced approaches followed by the PEGylated versions of hGH which is the preferred option of the established hGH marketers. Engineering of hGH to prolong half-life is a next generation approach already in early clinical development, but still requires injection. In contrast, non-injectable delivery approaches promise to avoid injection by oral, transdermal or nasal administration. There are numerous manufacturers of hGH in non-regulated markets, but most of them do not produce in a manner allowing approval in regulated markets although these products are frequently consumed by those interested in gaining muscle mass.

The report includes a compilation of current active projects in research and development of novel hGH products. Competitor projects are listed in a tabular format providing Information on:

* Drug Codes,

* Target / Mechanism of Action,

* Class of Compound,

* Company,

* Territory,

* Indication,

* R&D Stage and

* additional comments with a hyperlink leading to the source of information.

Index

2007 Market Size hGH

1st Generation: Somatropin in Regulated Markets

1st Generation: Biosimilar Somatropin in Regulated Markets

2nd Generation: Injectable Somatropin in SR Formulation in Regulated Markets

2nd Generation: Injectable PEGylated Somatropin in Regulated Markets

3rd Generation: Injectable Engineered Somatropin in Regulated Markets

4th Generation: Non-Injectable Somatropin in Regulated Markets

1st Generation: Somatropin in Non-Regulated Markets

2nd Generation: Injectable Somatropin in SR Formulation in Non-Regulated Markets

2nd Generation: Injectable PEGylated Somatropin in Non-Regulated Markets

Corporate R&D Pipelines for Human Growth Hormone (hGH):

* Altus Biopharmaceuticals

* Ambrx

* Anhui Anke Biotechnology

* Asterion

* Aegis Therapeutics

* Bio-ker

* Bio-Sidus

* Biocon

* BioPartners

* Biovel Life Sciences

* Bolder Biotechnology

* Cangene

* Critical Pharmaceuticals

* Daewoong Pharmaceutical

* Dainippon Sumitomo Pharma

* Dong-A Pharmaceutical Co

* Eli Lilly

* Emisphere Technologies

* Ferring

* Flamel Technologies

* Genentech

* GeneScience Pharmaceutical

* HanAll Pharmaceutical

* Hanmi Pharmaceutical

* Ipsen

* JCR Pharmaceutical

* LG Life Science

* Merck Serono

* Modigene

* Nanogene Biopharmaceutical

* Nautilus Biotech

* Neogenica Biosciences

* Neose Technologies

* Novo Nordisk

* OctoPlus

* Pfizer

* Phage Biotechnology

* PharmaEssentia

* Regeron

* Sandoz (Novartis)

* SciGen

* Shenzhen Kexing Biotech

* Tercica

* Teva Pharmaceutical Industries (CoGenesys; Sicor UAB Biotech)

* TransPharma Medical

About Competitor Analysis Series

The Competitor Analysis Series delivers NO-FRILLS , but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Publisher: La Merie

Product Line: Competitor Analysis

Pages 37

Release Date: October of 2008

Format: PDF

Product Code: LMCA004

Price

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions